However, in 2022, genome-wide association studies [98] have confirmed that ADAM23 and GRIA1, two components of a neuronal excitability synaptic complex, may explain genetic variation in a small subset of patients with early neurologic deterioration post-stroke as measured by a change in the NIH Stroke Scale. This evidence concerns the gene ADAM23 and stroke disorder.